Spravato 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
II/0021 
Update of the RMP to remove “use during pregnancy” 
08/02/2024 
n/a 
Please refer to Scientific Discussion 
as missing information from the list of safety 
concerns, with the consequential removal of the 
associated category 3 additional pharmacovigilance 
activity, the National Pregnancy Registry for 
Antidepressants. 
Spravato/H/C/004535/II/0021. For more information, 
please refer to the Summary of Product Characteristics. 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
II/0018 
Update of section 5.1 of the SmPC in order to add 
19/10/2023 
SmPC and PL 
Update of section 5.1 of the SmPC in order to add efficacy 
efficacy and safety information based on the final 
results from study 54135419TRD3013 (ESCAPE). 
This is A Randomized, Open-label, Rater-Blinded, 
Active-Controlled, International, Multicenter Study to 
Evaluate the Efficacy, Safety, and Tolerability of 
Flexibly Dosed Esketamine Nasal Spray Compared 
With Quetiapine Extended-Release in Adult and 
Elderly Participants With Treatment-Resistant Major 
Depressive Disorder Who are Continuing a Selective 
Serotonin Reuptake Inhibitor/Serotonin-
Norepinephrine Reuptake Inhibitor. 
In addition, the MAH took the opportunity to 
introduce minor editorial changes and to update the 
list of local representatives in the Package Leaflet. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
and safety information based on the final results from a 
Randomized, Open-label, Rater-Blinded, Active-Controlled, 
International, Multicenter Study to Evaluate the Efficacy, 
Safety, and Tolerability of Flexibly Dosed Esketamine Nasal 
Spray Compared With Quetiapine Extended-Release in 
Adult and Elderly Participants With Treatment-Resistant 
Major Depressive Disorder Who are Continuing a Selective 
Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine 
Reuptake Inhibitor. 
In addition, the MAH took the opportunity to introduce 
minor editorial changes and to update the list of local 
representatives in the Package Leaflet. 
For more information, please refer to the Summary of 
Product Characteristics. 
PSUSA/10825
Periodic Safety Update EU Single assessment - 
28/09/2023 
n/a 
PRAC Recommendation - maintenance 
/202303 
esketamine (for centrally authorised product only) 
Page 2/7 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0019/G 
This was an application for a group of variations. 
04/07/2023 
SmPC 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0016/G 
This was an application for a group of variations. 
05/05/2023 
n/a 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.b.2.a - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place 
PSUSA/10825
Periodic Safety Update EU Single assessment - 
13/10/2022 
09/12/2022 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202203 
esketamine (for centrally authorised product only) 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10825/202203. 
IAIN/0015 
B.II.e.5.a.1 - Change in pack size of the finished 
23/08/2022 
09/12/2022 
SmPC, 
product - Change in the number of units (e.g. 
Labelling and 
Page 3/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
PL 
IB/0013 
To extend the due date for a phase 3 study in the 
20/05/2022 
n/a 
To extend the due date for a phase 3 study in the RMP. 
RMP. 
C.I.11.z - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
II/0012 
Update to the SmPC Section 4.2, and Section 5.1, 
12/05/2022 
09/12/2022 
SmPC 
Update to the SmPC Section 4.2, and Section 5.1, based on 
based on the findings in Chinese subjects from a 
recently completed efficacy Phase 3 Study in adult 
with treatment-resistant depression. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
the findings in Chinese subjects from a recently completed 
efficacy Phase 3 Study in adult with treatment-resistant 
depression. This update can be justified by the results of 
the completed Phase 3 study ESKETINTRD3006. 
PSUSA/10825
Periodic Safety Update EU Single assessment - 
07/04/2022 
n/a 
PRAC Recommendation - maintenance 
/202109 
esketamine (for centrally authorised product only) 
PSUSA/10825
Periodic Safety Update EU Single assessment - 
30/09/2021 
n/a 
PRAC Recommendation - maintenance 
/202103 
esketamine (for centrally authorised product only) 
IB/0008 
C.I.11.z - Introduction of, or change(s) to, the 
21/06/2021 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IB/0009 
C.I.z - Changes (Safety/Efficacy) of Human and 
04/05/2021 
24/06/2022 
SmPC, Annex 
Veterinary Medicinal Products - Other variation 
II and PL 
Page 4/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10825
Periodic Safety Update EU Single assessment - 
09/04/2021 
n/a 
PRAC Recommendation - maintenance 
/202009 
esketamine (for centrally authorised product only) 
II/0004 
To update the Spravato Product Information at 
28/01/2021 
26/02/2021 
SmPC 
Please refer to Scientific Discussion ‘Product Name-H-C-
section 4.2 to replace the current dosing 
recommendation in patients with Japanese ancestry 
with a statement that efficacy of Spravato in 
Japanese patients has been studied but not 
established and to add information describing the 
study in section 5.1. The removal of the dosing 
recommendation for these patients is justified by the 
results of the completed Phase 2 study 
54135419TRD2005. 
The MAH took also the opportunity to update the 
Product information according to latest QRD template 
(v. 10.1) 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Product Number-II-Var.No’ 
SmPC new text 
Further to the results of the completed Phase 2 study 
54135419TRD2005, the PI has been updated to remove the 
current dosing recommendation in patients with Japanese 
ancestry with a statement that efficacy of Spravato in 
Japanese patients has been studied but not established in 
section 4.2 and to add also information describing the 
study in section 5.1. 
 For more information, please refer to the Summary of 
Product Characteristics. 
IB/0007 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
17/02/2021 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
II/0001/G 
This was an application for a group of variations. 
10/12/2020 
04/02/2021 
SmPC, Annex 
Please refer to Scientific Discussion ‘Spravato-H-C-Product 
C.I.6(a): Extension of Indication to include a new 
indication for Spravato: Spravato, co-administered 
II, Labelling 
Number-II-Var.No’ 
and PL 
The group of variations requested amendments to the 
Summary of Product Characteristics, Annex II, Labelling, 
Page 5/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
with oral antidepressant therapy, is indicated in 
adults with a moderate to severe episode of major 
depressive disorder, as acute short term treatment, 
for the rapid reduction of depressive symptoms, 
which according to clinical judgement constitute a 
psychiatric emergency (see section 5.1 for a 
description of the population studied). 
As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 
and 6.5 of the SmPC are updated. The RMP version 
2.5 has also been agreed. 
B.II.e.5.a.2: Addition of a new pack size (multipack) 
of 24 nasal spray devices (multipack of 8 packs of 3 
nasal spray devices) corresponding to 4 weeks of 
treatment in the new indication. 
The Package Leaflet and labelling are updated in 
accordance. In addition, the Marketing authorisation 
holder (MAH) took the opportunity to clarify the 
wording in Annex II.D. 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
Package Leaflet and Annex IV and to the Risk Management 
Plan (RMP). 
Extension of Indication to include a new indication for 
Spravato as follows: “Spravato, co-administered with oral 
antidepressant therapy, is indicated in adults with a 
moderate to severe episode of major depressive disorder, 
as acute short term treatment, for the rapid reduction of 
depressive symptoms, which according to clinical 
judgement constitute a psychiatric emergency (see section 
5.1 for a description of the population studied)” 
Addition of a new pack size (multipack) of 24 nasal spray 
devices (multipack of 8 packs of 3 nasal spray devices) 
corresponding to 4 weeks of treatment in the new 
indication. 
As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 6.5 
of the SmPC are updated. The RMP version 2.5 has also 
been agreed. 
The Package Leaflet and labelling are updated in 
accordance. In addition, the Marketing authorisation holder 
(MAH) took the opportunity to clarify the wording in Annex 
II.D.  
Changes were also made to the PI to bring it in line with 
the current Agency/QRD template, SmPC guideline and 
other relevant guideline(s) [e.g. Excipients guideline, 
storage conditions, Braille, etc…], which were reviewed and 
accepted by the CHMP. 
In addition, the list of local representatives in the PL has 
been revised to amend contact details for the 
representatives of Hungary. 
Page 6/7 
 
 
 
 
 
 
 
 
 
 
PSUSA/10825
Periodic Safety Update EU Single assessment - 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202003 
esketamine (for centrally authorised product only) 
IA/0005 
A.4 - Administrative change - Change in the name 
24/09/2020 
n/a 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
IB/0003 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
21/07/2020 
04/02/2021 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 7/7 
 
 
 
 
 
 
 
 
 
 
 
 
 
